MCID: JVN009
MIFTS: 43

Juvenile Pilocytic Astrocytoma

Categories: Cancer diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Juvenile Pilocytic Astrocytoma

MalaCards integrated aliases for Juvenile Pilocytic Astrocytoma:

Name: Juvenile Pilocytic Astrocytoma 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:6811
MeSH 42 D001254
NCIt 47 C27081
UMLS 69 C0280783

Summaries for Juvenile Pilocytic Astrocytoma

MalaCards based summary : Juvenile Pilocytic Astrocytoma is related to endotheliitis and pilocytic astrocytoma, and has symptoms including headache An important gene associated with Juvenile Pilocytic Astrocytoma is TIMP3 (TIMP Metallopeptidase Inhibitor 3), and among its related pathways/superpathways are Neuroscience and G-protein signaling Ras family GTPases in kinase cascades (scheme). The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone, and related phenotypes are behavior/neurological and cellular

Related Diseases for Juvenile Pilocytic Astrocytoma

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Juvenile Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 endotheliitis 30.1 ENO2 MBP
2 pilocytic astrocytoma 12.0
3 astrocytoma 10.7
4 pancreatic solid pseudopapillary carcinoma 10.7 NF1 NTM
5 congenital sucrase-isomaltase deficiency without starch intolerance 10.6 MAP2K1 TP53
6 cervical adenoid cystic carcinoma 10.6 CDKN2A TP53
7 pancoast tumor 10.6 GFAP TP53
8 renal pelvis urothelial papilloma 10.6 GFAP TP53
9 tendon sheath lipoma 10.6 GFAP TP53
10 split hand split foot nystagmus 10.5 CDKN2A TP53
11 leiomyoma cutis 10.5 CDKN2A TP53
12 anal squamous cell carcinoma 10.5 CDKN2A TP53
13 esophagus squamous cell carcinoma 10.5 CDKN2A FGF2 TP53
14 pleuropneumonia 10.4 CDKN2A MBP
15 fasciolopsiasis 10.4 CDKN2A TNC TP53
16 endometriosis of uterus 10.4 CDKN2A FGF2 TP53
17 c-p angle neurinoma 10.4 CDKN2A NF1 TP53
18 atrophic gastritis 10.4 CDKN2A FGF2 TP53
19 brain stem astrocytic neoplasm 10.4 GFAP NF1 TP53
20 chilaiditi syndrome 10.4 GFAP MBP
21 meningitis and encephalitis 10.4 ENO2 GFAP
22 cervical keratinizing squamous cell carcinoma 10.4 ENO2 NF1
23 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.4 GFAP TP53
24 enteric pattern testicular yolk sac tumor 10.3 ENO2 NF1
25 intellectual disability-polydactyly-uncombable hair syndrome 10.3 ENO2 GFAP
26 benign pleural mesothelioma 10.3 CDKN2A GFAP NF1
27 nail disorder, nonsyndromic congenital, 1 10.3 CDKN2A FGF2 TP53
28 nasopharyngeal carcinoma 10.3 CDKN2A NF1 TP53
29 nodular medulloblastoma 10.3 ENO2 GFAP
30 gestational choriocarcinoma 10.3 ENO2 FGF2 TP53
31 bladder urachal squamous cell carcinoma 10.3 CDKN2A NF1 TP53
32 plasmodium ovale malaria 10.3 CDKN2A GFAP TP53
33 congenital granular cell tumor 10.3 ENO2 TP53
34 integrative agnosia 10.3 ENO2 MBP
35 rectum squamous cell carcinoma 10.3 CDKN2A TP53
36 cystic lymphangioma 10.2 CDKN2A GFAP TP53
37 vestibular gland benign neoplasm 10.2 ENO2 NF1 TP53
38 glomus vagale tumor 10.2 CDKN2A FGF2 TNC TP53
39 postmenopausal atrophic vaginitis 10.2 ENO2 NF1 TP53
40 periventricular nodular heterotopia 6 10.2 CDKN2A GFAP TP53
41 hair disease 10.2 ENO2 TP53
42 breast myoepitheliosis 10.2 CDKN2A TP53
43 vulvar benign neoplasm 10.2 ENO2 GFAP
44 demyelinating disease 10.2 ENO2 GFAP NF1
45 olfactory neural tumor 10.2 CDKN2A ENO2 TP53
46 pancreatic agenesis 10.2 CDKN2A ENO2 TP53
47 internal auditory canal lipoma 10.2 CDKN2A ENO2 TP53
48 connective tissue cancer 10.2 ENO2 FGF2 GFAP
49 middle ear squamous cell carcinoma 10.2 CDKN2A ENO2 TP53
50 third cranial nerve disease 10.1 GFAP TP53

Graphical network of the top 20 diseases related to Juvenile Pilocytic Astrocytoma:



Diseases related to Juvenile Pilocytic Astrocytoma

Symptoms & Phenotypes for Juvenile Pilocytic Astrocytoma

UMLS symptoms related to Juvenile Pilocytic Astrocytoma:


headache

MGI Mouse Phenotypes related to Juvenile Pilocytic Astrocytoma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CD44 CDKN2A ENO2 FGF2 GFAP INSR
2 cellular MP:0005384 10.3 CD44 CDKN2A DDX3X ENO2 FGF2 GFAP
3 cardiovascular system MP:0005385 10.28 TP53 ZBTB20 CD44 CDKN2A DDX3X FGF2
4 growth/size/body region MP:0005378 10.27 CD44 CDKN2A DDX3X ENO2 GFAP INSR
5 homeostasis/metabolism MP:0005376 10.27 DDX3X FGF2 GFAP INSR MAP2K1 MBP
6 mortality/aging MP:0010768 10.18 CD44 CDKN2A DDX3X FGF2 GFAP INSR
7 nervous system MP:0003631 10.07 CD44 CDKN2A DDX3X ENO2 FGF2 GFAP
8 digestive/alimentary MP:0005381 10.05 GFAP INSR MAP2K1 NF1 TP53 CD44
9 muscle MP:0005369 10.02 CD44 CDKN2A DDX3X FGF2 GFAP INSR
10 liver/biliary system MP:0005370 9.98 CD44 CDKN2A INSR NF1 TIMP3 TP53
11 hearing/vestibular/ear MP:0005377 9.95 FGF2 MAP2K1 MBP NF1 TNC TP53
12 neoplasm MP:0002006 9.8 CD44 CDKN2A FGF2 MAP2K1 NF1 TP53
13 normal MP:0002873 9.76 CD44 DDX3X GFAP MAP2K1 MBP NF1
14 respiratory system MP:0005388 9.5 CD44 CDKN2A ENO2 INSR NF1 TIMP3
15 vision/eye MP:0005391 9.32 CD44 CDKN2A FGF2 GFAP MAP2K1 MBP

Drugs & Therapeutics for Juvenile Pilocytic Astrocytoma

Drugs for Juvenile Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 2068-78-2, 57-22-7 5978
4
Lomustine Approved Phase 2, Phase 3 13010-47-4 3950
5
Procarbazine Approved Phase 2, Phase 3 671-16-9 4915
6
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Alkylating Agents Phase 2, Phase 3,Phase 1
12 Dermatologic Agents Phase 3,Phase 2,Phase 1
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Central Nervous System Depressants Phase 3
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Narcotics Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Cholinergic Agents Phase 3,Phase 2
24 Cholinesterase Inhibitors Phase 3,Phase 2
25 Neurotransmitter Agents Phase 3,Phase 2
26 Nootropic Agents Phase 3,Phase 2
27 Antimitotic Agents Phase 2, Phase 3,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
29 Gastrointestinal Agents Phase 3,Phase 1
30 Central Nervous System Stimulants Phase 3,Phase 2
31 Dopamine Agents Phase 3
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34 Histamine Antagonists Phase 3
35 Histamine H1 Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Phase 3 50-67-9 5202
38 Serotonin Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Dexmethylphenidate Hydrochloride Phase 3
41 Dopamine Uptake Inhibitors Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Cola Nutraceutical Phase 3,Phase 1
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
47
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
48
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
49
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
50
Carmustine Approved Phase 2,Phase 1 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 66)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
6 Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma Unknown status NCT00003471 Phase 2 antineoplaston A10;antineoplaston AS2-1
7 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
8 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
9 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
10 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
11 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
12 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
13 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
14 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
15 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
16 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
17 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
18 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
20 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
21 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
22 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
23 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
24 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
25 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
26 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
27 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2 Temozolomide
28 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
29 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
30 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
31 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
32 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
33 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
34 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
35 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
36 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
37 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
38 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
39 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
40 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
41 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
42 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
43 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
44 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
45 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
46 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
47 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
48 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
49 Cognitive Biomarkers in Pediatric Brain Tumor Patients Recruiting NCT02914067 Phase 1
50 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide

Search NIH Clinical Center for Juvenile Pilocytic Astrocytoma

Genetic Tests for Juvenile Pilocytic Astrocytoma

Anatomical Context for Juvenile Pilocytic Astrocytoma

MalaCards organs/tissues related to Juvenile Pilocytic Astrocytoma:

39
Brain, Liver, Bone, Kidney, Spinal Cord, Pituitary, Pineal

Publications for Juvenile Pilocytic Astrocytoma

Articles related to Juvenile Pilocytic Astrocytoma:

(show all 48)
id Title Authors Year
1
Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. ( 27314542 )
2016
2
Spontaneous aneurysmal subarachnoid haemorrhage in a child with multiply recurrent posterior fossa juvenile pilocytic astrocytoma. ( 27927709 )
2016
3
Preoperative Presentation of a Variant of Cerebellar Mutism Syndrome in a Young Boy With Juvenile Pilocytic Astrocytoma. ( 26145481 )
2015
4
Hodgkin's lymphoma in an adolescent previously treated with surgical resection of third ventricular juvenile pilocytic astrocytoma. ( 26113587 )
2015
5
Peduncular Hallucinosis as First Presentation of Juvenile Pilocytic Astrocytoma. ( 26548431 )
2015
6
Intracranial organizing hematoma with papillary endothelial hyperplasia features after resection and involved field radiotherapy for cerebellar juvenile pilocytic astrocytoma. ( 24456989 )
2014
7
A case of central precocious puberty due to concomitant hypothalamic hamartoma and juvenile pilocytic astrocytoma. ( 25241615 )
2014
8
An unbalanced translocation involving loss of 10q26.2 and gain of 11q25 in a pedigree with autism spectrum disorder and cerebellar juvenile pilocytic astrocytoma. ( 23495067 )
2013
9
Retrocochlear hearing loss in infants: a case study of juvenile pilocytic astrocytoma. ( 22642312 )
2012
10
Secondary glioblastoma multiforme in a child with disseminated juvenile pilocytic astrocytoma. ( 23227384 )
2012
11
Juvenile pilocytic astrocytoma in association with arteriovenous malformation. ( 22681727 )
2012
12
Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. ( 21572348 )
2011
13
Picture of the month--quiz case. Lisch nodules, ectropion uveae, and optic pathway glioma (juvenile pilocytic astrocytoma) due to neurofibromatosis type 1. ( 20439802 )
2010
14
Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report. ( 20121362 )
2010
15
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. ( 19603027 )
2009
16
Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. ( 19951034 )
2009
17
Long-term functional outcome of surgical treatment of juvenile pilocytic astrocytoma of the cerebellum in children. ( 19418058 )
2009
18
Supratentorial juvenile pilocytic astrocytoma in a young adult with Silver-Russell syndrome. ( 18661310 )
2008
19
Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle. ( 18255162 )
2008
20
Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. ( 16206208 )
2006
21
Excision of juvenile pilocytic astrocytoma of the midbrain after radiotherapy. ( 16902345 )
2006
22
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. ( 15665281 )
2005
23
Oligodendroglioma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors. Case report with histological and molecular differentiation of the tumors and review of the literature. ( 15070126 )
2004
24
Juvenile pilocytic astrocytoma presenting with subarachnoid hemorrhage. Case report and review of the literature. ( 15287467 )
2004
25
Juvenile pilocytic astrocytoma 'pilomyxoid variant' with spinal metastases. ( 15261239 )
2004
26
Juvenile pilocytic astrocytoma of the brainstem in children. ( 16206964 )
2004
27
Juvenile pilocytic astrocytoma. ( 12880155 )
2003
28
Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optico-hypothalamic juvenile pilocytic astrocytoma in an infant: a case report. ( 12777080 )
2003
29
Case report: Hemispheric juvenile pilocytic astrocytoma with extreme exophytic growth. ( 11384146 )
2001
30
Spontaneous cerebellar hemorrhage due to a juvenile pilocytic astrocytoma: case report and review of the literature. ( 11423772 )
2001
31
Concurrent acute lymphoblastic leukemia and juvenile pilocytic astrocytoma in a pediatric patient. ( 11037859 )
2000
32
High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. ( 10416986 )
1999
33
Multicentric juvenile pilocytic astrocytoma occurring primarily in the trigone of the lateral ventricle. ( 10502010 )
1999
34
Hypothalamic juvenile pilocytic astrocytoma presenting with intracerebral hemorrhage. ( 9872037 )
1998
35
Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. ( 9524106 )
1998
36
Juvenile pilocytic astrocytoma masquerading as amblyopia. ( 9152078 )
1997
37
Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. ( 9210720 )
1997
38
Normal evoked otoacoustic emissions with a profound hearing loss due to a juvenile pilocytic astrocytoma. ( 8841714 )
1996
39
Deletion of chromosome arm 17p DNA sequences in pediatric high-grade and juvenile pilocytic astrocytomas. ( 7536455 )
1995
40
Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. ( 8207524 )
1994
41
Leptomeningeal dissemination of juvenile pilocytic astrocytoma: case report. ( 8165503 )
1994
42
Radiation therapy for juvenile pilocytic astrocytoma of the pituitary stalk. Case report. ( 1607955 )
1992
43
Metastatic juvenile pilocytic astrocytoma. Case report. ( 1941128 )
1991
44
Juvenile pilocytic astrocytoma of the optic nerve diagnosed by fine needle aspiration biopsy. ( 3376707 )
1988
45
Treatment results of juvenile pilocytic astrocytoma. ( 3392563 )
1988
46
Juvenile pilocytic astrocytoma of the cerebrum in adults. A distinctive neoplasm with favorable prognosis. ( 4020465 )
1985
47
Juvenile pilocytic astrocytoma of the pineal region: report of a case. ( 7104961 )
1982
48
Isolated trochlear nerve palsy secondary to a juvenile pilocytic astrocytoma. ( 6226694 )
1982

Variations for Juvenile Pilocytic Astrocytoma

Expression for Juvenile Pilocytic Astrocytoma

Search GEO for disease gene expression data for Juvenile Pilocytic Astrocytoma.

Pathways for Juvenile Pilocytic Astrocytoma

GO Terms for Juvenile Pilocytic Astrocytoma

Biological processes related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDKN2A FGF2 INSR MAP2K1 TP53
2 MAPK cascade GO:0000165 9.71 FGF2 MAP2K1 MBP NF1
3 activation of MAPK activity GO:0000187 9.69 FGF2 INSR MAP2K1
4 wound healing GO:0042060 9.61 FGF2 NF1 TNC
5 positive regulation of gene expression GO:0010628 9.56 DDX3X MAP2K1 TNC TP53
6 negative regulation of cell-matrix adhesion GO:0001953 9.49 CDKN2A NF1
7 hyaluronan catabolic process GO:0030214 9.46 CD44 FGF2
8 replicative senescence GO:0090399 9.37 CDKN2A TP53
9 extracellular matrix organization GO:0030198 9.26 CD44 FGF2 NF1 TNC
10 neuron recognition GO:0008038 9.16 NTM OPCML
11 Bergmann glial cell differentiation GO:0060020 9.02 MAP2K1
12 Ras protein signal transduction GO:0007265 8.92 CDKN2A FGF2 NF1 TP53

Molecular functions related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.26 CDKN2A DDX3X MLX TP53
2 protease binding GO:0002020 8.8 MBP TIMP3 TP53

Sources for Juvenile Pilocytic Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....